Home
PHIO
PHIO News

Latest Phio Pharmaceuticals Corp. (PHIO) News on September 14, 2025

Phio Pharmaceuticals Announces Positive Safety Monitoring Committee Recommendation to Advance INTASYL PH-762 Skin Cancer Clinical Trial to Fifth Dose Escalation Cohort

Newsfile

3 months ago

Phio Pharmaceuticals Announces Positive Safety Monitoring Committee Recommendation to Advance INTASYL PH-762 Skin Cancer Clinical Trial to Fifth Dose Escalation Cohort

Phio Pharmaceuticals Announces Participation in the Renmark Financial Communications Virtual Non-Deal Roadshow Series

Newsfile

3 months ago

Phio Pharmaceuticals Announces Participation in the Renmark Financial Communications Virtual Non-Deal Roadshow Series

Phio Pharmaceuticals Announces Strategic Initiative to Create Awareness of the Comprehensive INTASYL siRNA Portfolio

Newsfile

3 months ago

Phio Pharmaceuticals Announces Strategic Initiative to Create Awareness of the Comprehensive INTASYL siRNA Portfolio

Best Value Stocks to Buy for May 28th

Zacks

4 months ago

Best Value Stocks to Buy for May 28th

New Strong Buy Stocks for May 28th

Zacks

4 months ago

New Strong Buy Stocks for May 28th

Sidoti Events, LLC's Virtual May Micro-Cap Conference

ACCESS Newswire

4 months ago

Sidoti Events, LLC's Virtual May Micro-Cap Conference

Phio Pharmaceuticals Announces Participation in the Sidoti Micro-Cap Virtual Investor Conference

Newsfile

4 months ago

Phio Pharmaceuticals Announces Participation in the Sidoti Micro-Cap Virtual Investor Conference

Phio Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update

Newsfile

4 months ago

Phio Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update

Phio Pharmaceuticals Announces Positive Pathology Results in Third Cohort in INTASYL PH-762 Skin Cancer Clinical Trial

Newsfile

4 months ago

Phio Pharmaceuticals Announces Positive Pathology Results in Third Cohort in INTASYL PH-762 Skin Cancer Clinical Trial

Phio Pharmaceuticals Announces Participation in the Renmark Financial Communications Virtual Non-Deal Roadshow Series

Newsfile

4 months ago

Phio Pharmaceuticals Announces Participation in the Renmark Financial Communications Virtual Non-Deal Roadshow Series

Best Momentum Stocks to Buy for April 23rd

Zacks

5 months ago

Best Momentum Stocks to Buy for April 23rd

Best Value Stocks to Buy for April 23rd

Zacks

5 months ago

Best Value Stocks to Buy for April 23rd

PHIO Stock Soars as Safety Panel Clears Skin Cancer Drug for Next Dose

Zacks

5 months ago

PHIO Stock Soars as Safety Panel Clears Skin Cancer Drug for Next Dose

MT Newswires

5 months ago

Sector Update: Health Care Stocks Fall Premarket Wednesday

MT Newswires

5 months ago

Phio Pharmaceuticals Potential Skin Cancer Treatment Recommended for Dose Escalation

Phio Pharmaceuticals Announces Positive Safety Monitoring Committee Recommendation to Advance INTASYL PH-762 Skin Cancer Study to Fourth Dose Escalation Cohort

Newsfile

5 months ago

Phio Pharmaceuticals Announces Positive Safety Monitoring Committee Recommendation to Advance INTASYL PH-762 Skin Cancer Study to Fourth Dose Escalation Cohort

Phio Pharmaceuticals Announces Podium Presentations on INTASYL siRNA Lead Product Candidates PH-762 and PH-894

Newsfile

5 months ago

Phio Pharmaceuticals Announces Podium Presentations on INTASYL siRNA Lead Product Candidates PH-762 and PH-894

Phio Pharmaceuticals Reports 2024 Year End Financial Results and Provides Business Update

Newsfile

5 months ago

Phio Pharmaceuticals Reports 2024 Year End Financial Results and Provides Business Update

American Academy of Dermatology Awards Podium Presentation to Phio Pharmaceutical's Clinical Research at 2025 Annual Meeting

Newsfile

6 months ago

American Academy of Dermatology Awards Podium Presentation to Phio Pharmaceutical's Clinical Research at 2025 Annual Meeting

Phio Pharmaceuticals Announces Completion of Enrollment in Third Safety Cohort in PH-762 Phase 1b Dose-Escalation Study

Newsfile

6 months ago

Phio Pharmaceuticals Announces Completion of Enrollment in Third Safety Cohort in PH-762 Phase 1b Dose-Escalation Study

Phio Pharmaceuticals Announces Participation in the Renmark Financial Communications Virtual Non-Deal Roadshow Series

Newsfile

7 months ago

Phio Pharmaceuticals Announces Participation in the Renmark Financial Communications Virtual Non-Deal Roadshow Series

Phio Pharmaceuticals Announces Appointment of David H. Deming to Board of Directors

Newsfile

7 months ago

Phio Pharmaceuticals Announces Appointment of David H. Deming to Board of Directors

Phio Pharmaceuticals Announces Participation in the Renmark Financial Communications Virtual Non-Deal Roadshow Series

Newsfile

7 months ago

Phio Pharmaceuticals Announces Participation in the Renmark Financial Communications Virtual Non-Deal Roadshow Series

Phio Pharmaceuticals to Participate in the Renmark Financial Communications Virtual Non-Deal Roadshow Series

Newsfile

8 months ago

Phio Pharmaceuticals to Participate in the Renmark Financial Communications Virtual Non-Deal Roadshow Series

MT Newswires

8 months ago

Phio Files Registration Statement for Share Resale

Phio Pharmaceuticals Announces Closing of $1.83 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Newsfile

8 months ago

Phio Pharmaceuticals Announces Closing of $1.83 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Newsfile

8 months ago

Phio Pharmaceuticals Announces $1.83 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Phio Pharmaceuticals Announces $2.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Newsfile

8 months ago

Phio Pharmaceuticals Announces $2.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

MT Newswires

8 months ago

Phio Pharmaceuticals Unveils $3.2 Million Registered Direct Offering; Shares Fall

MT Newswires

8 months ago

Top Premarket Decliners

Phio Pharmaceuticals Announces $3.19 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Newsfile

8 months ago

Phio Pharmaceuticals Announces $3.19 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Cancer-Focused Phio Pharmaceuticals Stock Gains 300% On Monday - Here's Why

Benzinga

8 months ago

Cancer-Focused Phio Pharmaceuticals Stock Gains 300% On Monday - Here's Why

Phio Pharmaceuticals Announces Promising Results of Second Cohort from Its Ongoing Clinical Study of PH-762

Newsfile

8 months ago

Phio Pharmaceuticals Announces Promising Results of Second Cohort from Its Ongoing Clinical Study of PH-762

Phio Pharmaceuticals Announces Publication in Clinical, Cosmetic and Investigational Dermatology

Newsfile

8 months ago

Phio Pharmaceuticals Announces Publication in Clinical, Cosmetic and Investigational Dermatology

Phio Pharmaceuticals Announces Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Newsfile

9 months ago

Phio Pharmaceuticals Announces Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Phio Pharmaceuticals Announces $1.15 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Newsfile

9 months ago

Phio Pharmaceuticals Announces $1.15 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

MT Newswires

9 months ago

Phio Pharmaceuticals Safety Panel Approves Dose Escalation in Skin Cancer Trial

Phio Pharmaceuticals Announces Positive Safety Monitoring Committee (SMC) Recommendation to Continue to Third Dose Cohort in its Clinical Study of PH-762

Newsfile

9 months ago

Phio Pharmaceuticals Announces Positive Safety Monitoring Committee (SMC) Recommendation to Continue to Third Dose Cohort in its Clinical Study of PH-762

Phio Pharmaceuticals Announces Publication in Frontiers in Immunology

Newsfile

9 months ago

Phio Pharmaceuticals Announces Publication in Frontiers in Immunology

Phio Pharmaceuticals is a Finalist for the Technology Disruptor of the Year Award

Newsfile

9 months ago

Phio Pharmaceuticals is a Finalist for the Technology Disruptor of the Year Award

Phio Pharmaceuticals to Participate in the Renmark Financial Communications Virtual Non-Deal Roadshow Series

Newsfile

9 months ago

Phio Pharmaceuticals to Participate in the Renmark Financial Communications Virtual Non-Deal Roadshow Series

Phio Pharmaceuticals Announces Completion of Enrollment in Second Cohort in Phase 1b Dose-Escalating Clinical Study

Newsfile

10 months ago

Phio Pharmaceuticals Announces Completion of Enrollment in Second Cohort in Phase 1b Dose-Escalating Clinical Study

Newsfile

10 months ago

Phio Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Update

Phio Pharmaceuticals Announces Upcoming Presentation at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)

Newsfile

10 months ago

Phio Pharmaceuticals Announces Upcoming Presentation at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)

Phio Pharmaceuticals to Participate in the Renmark Financial Communications Virtual Non-Deal Roadshow Series

Newsfile

10 months ago

Phio Pharmaceuticals to Participate in the Renmark Financial Communications Virtual Non-Deal Roadshow Series

Phio Pharmaceuticals Announces Upcoming Presentation at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)

Newsfile

a year ago

Phio Pharmaceuticals Announces Upcoming Presentation at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)

Correction to Registration Link to Access Phio Pharmaceuticals' Presentation in the Renmark Financial Communications Virtual Non-Deal Roadshow Series

Newsfile

a year ago

Correction to Registration Link to Access Phio Pharmaceuticals' Presentation in the Renmark Financial Communications Virtual Non-Deal Roadshow Series

Phio Pharmaceuticals to Participate in the Renmark Financial Communications Virtual Non-deal Roadshow Series

Newsfile

a year ago

Phio Pharmaceuticals to Participate in the Renmark Financial Communications Virtual Non-deal Roadshow Series

Phio Pharmaceuticals Presenting Data on Its INSTAYL Compound PH-894 at ASGCT's 2024 Advancing Gene and Cell Therapies for Cancer Conference

Newsfile

a year ago

Phio Pharmaceuticals Presenting Data on Its INSTAYL Compound PH-894 at ASGCT's 2024 Advancing Gene and Cell Therapies for Cancer Conference

Phio Announces Data Showcasing INTASYL's Role in Helping Immune Cells Target and Kill Cancer Cells

Newsfile

a year ago

Phio Announces Data Showcasing INTASYL's Role in Helping Immune Cells Target and Kill Cancer Cells

Phio Pharmaceuticals to Participate in the Renmark Financial Communications Virtual Non-Deal Roadshow Series

Newsfile

a year ago

Phio Pharmaceuticals to Participate in the Renmark Financial Communications Virtual Non-Deal Roadshow Series

Phio Pharmaceuticals Announces Upcoming Presentation at ASGCT's 2024 Advancing Gene + Cell Therapies for Cancer Conference

Newsfile

a year ago

Phio Pharmaceuticals Announces Upcoming Presentation at ASGCT's 2024 Advancing Gene + Cell Therapies for Cancer Conference

INTASYL Technology and Compounds to be Focus of Presentation at 20th Annual Meeting of Oligonucleotide Therapeutics Society

Newsfile

a year ago

INTASYL Technology and Compounds to be Focus of Presentation at 20th Annual Meeting of Oligonucleotide Therapeutics Society

Phio Pharmaceuticals to Participate in the Renmark Financial Communications Virtual Non-Deal Roadshow Series

Newsfile

a year ago

Phio Pharmaceuticals to Participate in the Renmark Financial Communications Virtual Non-Deal Roadshow Series

Phio Pharmaceuticals Announces Presentation at the 9th Annual CAR-TCR Summit in Boston, MA

Newsfile

a year ago

Phio Pharmaceuticals Announces Presentation at the 9th Annual CAR-TCR Summit in Boston, MA

Phio Pharmaceuticals to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Newsfile

a year ago

Phio Pharmaceuticals to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Phio Pharmaceuticals to Participate in the Renmark Financial Communications Virtual Non-Deal Roadshow Series

Newsfile

a year ago

Phio Pharmaceuticals to Participate in the Renmark Financial Communications Virtual Non-Deal Roadshow Series

Phio Pharmaceuticals Corp.'s (NASDAQ:PHIO) Path To Profitability

Simply Wall St.

a year ago

Phio Pharmaceuticals Corp.'s (NASDAQ:PHIO) Path To Profitability

Phio Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Business Update

Newsfile

a year ago

Phio Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Business Update

Phio Pharmaceuticals Announces Exploratory Collaboration with a Luxury Skin Care Company for Phio's Patented INTASYL Compound

Newsfile

a year ago

Phio Pharmaceuticals Announces Exploratory Collaboration with a Luxury Skin Care Company for Phio's Patented INTASYL Compound

Phio Pharmaceuticals Announces New Chief Financial Officer

Newsfile

a year ago

Phio Pharmaceuticals Announces New Chief Financial Officer

Phio Pharmaceuticals Announces Exercise of Warrants for $3.1 Million Gross Proceeds

Newsfile

a year ago

Phio Pharmaceuticals Announces Exercise of Warrants for $3.1 Million Gross Proceeds

Phio Pharmaceuticals Announces Addition of Clinical Trial Site for its Phase 1b study of PH-762

Newsfile

a year ago

Phio Pharmaceuticals Announces Addition of Clinical Trial Site for its Phase 1b study of PH-762

Phio Pharmaceuticals Terminates Share Purchase Agreement with Triton Funds

Newsfile

a year ago

Phio Pharmaceuticals Terminates Share Purchase Agreement with Triton Funds

MT Newswires

a year ago

Phio Pharmaceuticals Board Approves 1-For-9 Reverse Stock Split

Phio Pharmaceuticals Announces Reverse Stock Split

Newsfile

a year ago

Phio Pharmaceuticals Announces Reverse Stock Split

Phio Pharmaceuticals Announces New Patent for INTASYL Compound That Targets Photo-aging

Newsfile

a year ago

Phio Pharmaceuticals Announces New Patent for INTASYL Compound That Targets Photo-aging

Phio Pharmaceuticals Announces Positive Recommendation from Safety Monitoring Committee (SMC) of Phase 1b Clinical Study of Phio's Lead Compound PH-762

Newsfile

a year ago

Phio Pharmaceuticals Announces Positive Recommendation from Safety Monitoring Committee (SMC) of Phase 1b Clinical Study of Phio's Lead Compound PH-762

Phio Pharmaceuticals Announces Presentation at the Annual Meeting of the American Society of Clinical Oncology (ASCO)

Newsfile

a year ago

Phio Pharmaceuticals Announces Presentation at the Annual Meeting of the American Society of Clinical Oncology (ASCO)

MT Newswires

a year ago

Phio Pharmaceuticals Files $100 Million Mixed Shelf

Phio Pharmaceuticals Secures New Investor

GlobeNewswire

a year ago

Phio Pharmaceuticals Secures New Investor

Phio Pharmaceuticals Presents This Week at the Society for Investigative Dermatology (SID)

GlobeNewswire

a year ago

Phio Pharmaceuticals Presents This Week at the Society for Investigative Dermatology (SID)

MT Newswires

a year ago

Phio Pharmaceuticals Doses 1st Group in Skin Cancer Treatment Study

Phio Pharmaceuticals Announces Completion of Dosing in First Patient Cohort in PH-762 Phase 1b Dose-Escalation Study

GlobeNewswire

a year ago

Phio Pharmaceuticals Announces Completion of Dosing in First Patient Cohort in PH-762 Phase 1b Dose-Escalation Study

Phio Pharmaceuticals Reports Q1 2024 Results and Provides Business Update

GlobeNewswire

a year ago

Phio Pharmaceuticals Reports Q1 2024 Results and Provides Business Update

Phio Pharmaceuticals Announces Upcoming Presentation at the Annual Meeting of the Society of Clinical Oncology (ASCO)

GlobeNewswire

a year ago

Phio Pharmaceuticals Announces Upcoming Presentation at the Annual Meeting of the Society of Clinical Oncology (ASCO)

Intratumoral Injection of Phio’s PH-762 significantly inhibits tumor growth in murine tumor models and may generate memory-specific T cells

GlobeNewswire

a year ago

Intratumoral Injection of Phio’s PH-762 significantly inhibits tumor growth in murine tumor models and may generate memory-specific T cells

Phio Pharmaceuticals Announces Upcoming Presentations at the 81st Annual Meeting of the Society for Investigative Dermatology (SID)

GlobeNewswire

a year ago

Phio Pharmaceuticals Announces Upcoming Presentations at the 81st Annual Meeting of the Society for Investigative Dermatology (SID)

Phio Pharmaceuticals Announces Upcoming Presentation at the 27th Annual Meeting of the American Society of Cell and Gene Therapy (ASCGT)

GlobeNewswire

a year ago

Phio Pharmaceuticals Announces Upcoming Presentation at the 27th Annual Meeting of the American Society of Cell and Gene Therapy (ASCGT)

National Spotlight Features Phio’s Innovative RNAi Technology Platform

GlobeNewswire

a year ago

National Spotlight Features Phio’s Innovative RNAi Technology Platform

Phio Pharmaceuticals Reports 2023 Year End Financial Results and Provides Business Update

GlobeNewswire

a year ago

Phio Pharmaceuticals Reports 2023 Year End Financial Results and Provides Business Update

Phio Pharmaceuticals Presenting Data Showing INTASYL May Result in More Effective Cell Therapy for Hematological Malignancies

GlobeNewswire

a year ago

Phio Pharmaceuticals Presenting Data Showing INTASYL May Result in More Effective Cell Therapy for Hematological Malignancies

Phio Pharmaceuticals Announces Addition of Clinical Trial Sites at Banner MD Anderson Cancer Center, The George Washington University, and Integrity Research

GlobeNewswire

2 years ago

Phio Pharmaceuticals Announces Addition of Clinical Trial Sites at Banner MD Anderson Cancer Center, The George Washington University, and Integrity Research

Phio Pharmaceuticals Announces Patent Granted by USPTO, Strengthening the Company’s Intellectual Property Position in Treating Aging Skin and Skin Disorders

GlobeNewswire

2 years ago

Phio Pharmaceuticals Announces Patent Granted by USPTO, Strengthening the Company’s Intellectual Property Position in Treating Aging Skin and Skin Disorders

Phio Pharmaceuticals Announces Data Showing INTASYL May Result in More Effective Cell Therapy for Hematological Malignancies

GlobeNewswire

2 years ago

Phio Pharmaceuticals Announces Data Showing INTASYL May Result in More Effective Cell Therapy for Hematological Malignancies

Inhibikase Therapeutics Announces Publication Highlighting Results from its Phase 1 Studies with Risvodetinib

GlobeNewswire

2 years ago

Inhibikase Therapeutics Announces Publication Highlighting Results from its Phase 1 Studies with Risvodetinib

Gamida Cell Actively Pursuing Strategic Alternatives

GlobeNewswire

2 years ago

Gamida Cell Actively Pursuing Strategic Alternatives

Lexaria Releases Annual Letter from the CEO

ACCESSWIRE

2 years ago

Lexaria Releases Annual Letter from the CEO

Hoth Therapeutics Announces it Received FDA Approval to Expand HT-001 Clinical Trial to Treat Severely Ill Patients

PR Newswire

2 years ago

Hoth Therapeutics Announces it Received FDA Approval to Expand HT-001 Clinical Trial to Treat Severely Ill Patients

DecisionPoint (DPSI) Unveils PointCare to Offer Tech Services

Zacks

2 years ago

DecisionPoint (DPSI) Unveils PointCare to Offer Tech Services

Sidoti Events, LLC's Virtual January Micro-Cap Conference

ACCESSWIRE

2 years ago

Sidoti Events, LLC's Virtual January Micro-Cap Conference

Theriva Biologics to Participate in the B. Riley Securities Annual Oncology Conference

GlobeNewswire

2 years ago

Theriva Biologics to Participate in the B. Riley Securities Annual Oncology Conference

Delcath Systems Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

PR Newswire

2 years ago

Delcath Systems Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Foremost Lithium Receives Multi-Year Work Permit to Commence Drilling on its Jean Lake Lithium/Gold Property

GlobeNewswire

2 years ago

Foremost Lithium Receives Multi-Year Work Permit to Commence Drilling on its Jean Lake Lithium/Gold Property

Urban Farming Frontiers: 3 Stocks Growing Greens in the City

InvestorPlace

2 years ago

Urban Farming Frontiers: 3 Stocks Growing Greens in the City

Foremost Lithium Announces Receipt of Third $300,000 Grant from The Manitoba Mineral Development Fund (MMDF)

GlobeNewswire

2 years ago

Foremost Lithium Announces Receipt of Third $300,000 Grant from The Manitoba Mineral Development Fund (MMDF)

OSS Joins Two Key U.S. DoD Consortiums, SCEC and SOSSEC

GlobeNewswire

2 years ago

OSS Joins Two Key U.S. DoD Consortiums, SCEC and SOSSEC

BTC Digital Ltd. Announces Purchase of 2,000 Units of T21 Miners

PR Newswire

2 years ago

BTC Digital Ltd. Announces Purchase of 2,000 Units of T21 Miners

BTC Digital Ltd. Announces Entry into Share Subscription Agreements in Connection with Private Placement of Ordinary Shares

PR Newswire

2 years ago

BTC Digital Ltd. Announces Entry into Share Subscription Agreements in Connection with Private Placement of Ordinary Shares

Daré Bioscience Secures $12 million in Royalty-backed Investment Structure

GlobeNewswire

2 years ago

Daré Bioscience Secures $12 million in Royalty-backed Investment Structure

Share on Social Networks: